twoXAR Announces Appointment of Allen Poirson, Ph.D. as Senior Vice President of Biopharmaceutical Business Development

Dr. Poirson’s experience includes serving as Chief Executive Officer for Sony Biotechnology, a wholly-owned subsidiary of Sony Corporation of America that develops and manufactures instruments used for researching and developing pharmaceuticals. Most recently, Dr. Poirson was a Partner at Mighty Capital, a Silicon Valley-based venture capital firm, where he was responsible for investments in digital health, life science, and medical companies. While serving as Director of Scientific Programs and Licensing at the Glaucoma Research Foundation, Dr. Poirson drove research for a neurodegenerative approach for treating glaucoma and negotiated intellectual property agreements. He has held research positions at NASA and the Howard Hughes Medical Institute and received his doctorate and bachelor of arts degree from Stanford University.

“Allen’s experience forging strategic alliances in the life sciences industry will be a tremendous asset to twoXAR as the company continues to partner with leading biopharmaceutical companies to discover and develop first-in-class treatments for a wide range of diseases,” said Andrew A. Radin, co-founder and CEO of twoXAR. “This is an exciting time for our company, and we are thrilled to welcome Allen to the team. His impressive experience will help us achieve our vision to become the global leader in drug discovery and development by developing new medicines to benefit billions of patients.”

“I am excited to join twoXAR’s exceptional team and help further the company’s mission to accelerate drug discovery and development of new therapies for diseases that currently lack effective solutions,” said Dr. Poirson. “twoXAR’s game-changing approach leverages artificial intelligence to rapidly identify new drug candidates, and I look forward to building strategic partnerships to help bring more treatments to patients.”

twoXAR’s artificial intelligence-driven approach is designed to better equip experts in the process of drug discovery by rapidly de-risking opportunities and eliminating a multi-step approach that severely limits the pace of drug discovery. The company’s novel platform uses proprietary algorithms to combine and analyze existing diverse datasets from the real world to increase early-stage success rates and allow for in vivo testing of drug candidates in as little as a month – bypassing the traditional process that typically takes 4-6 years.

About twoXAR

twoXAR is an artificial intelligence-driven biopharmaceutical company based in Mountain View, California. The company’s mission is to usher in a new era of rapid and efficient drug discovery and development to accelerate new therapies for diseases that currently lack effective solutions. The company currently has a portfolio of more than 18 programs underway, internally and through partnerships, to discover and develop first-in-class treatments for a wide range of diseases. Investors in twoXAR include SoftBank Ventures, Andreessen Horowitz, OS Fund, CLI Ventures, and the Stanford-StartX Fund. To learn more, visit www.twoxar.com, or follow the company on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005322/en/